Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
A Study of IMU-201 (PD1-Vaxx) a B-Cell Immunotherapy in Adults With Non-Small Cell Lung Cancer

The phase 1 study is an open label, multi-center, non-randomized, dose escalation and expansion study designed to assess the safety, tolerability, and immunogenicity of IMU-201(PD1-Vaxx) as monotherapy in patients with PD-L1 expressing non-small cell lung cancer (NSCLC).

lung carcinoma
pd-l1
adenocarcinoma
platelet count
carcinoma
  • 0 views
  • 28 May, 2021
  • 7 locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

systemic therapy
carboplatin
proto-oncogene tyrosine-protein kinase ros
NTRK
pemetrexed
  • 389 views
  • 10 Jun, 2021
  • 79 locations
Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

in the first-line treatment of 54 wild-type advanced NSCLC patients with carboplatin and pemetrexed showed that the ORR, mPFS and mOS of patients with wild-type non-squamous NSCLC treated with

  • 0 views
  • 24 Jan, 2021
  • 1 location
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

. The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3

  • 0 views
  • 26 Jan, 2021
  • 1 location
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …

concurrent chemotherapy
serum bilirubin
recurrent non-small cell lung cancer
metastasis
targeted therapy
  • 175 views
  • 09 May, 2021
  • 747 locations
Safety Tolerability and Pharmacokinetics of Oral CPL304110 in Adult Subjects With Advanced Solid Malignancies

The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.

formalin-fixed paraffin-embedded
bladder tumor
sarcoma
bladder cancer
measurable disease
  • 32 views
  • 27 Jan, 2021
  • 12 locations
Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

Lung cancer is diagnosed at metastatic stage in 60% of the cases. For these patients, first-line treatment is based on histology and molecular characterization of non-squamous non-small cell

ROS1
c-MET
cancer treatment
LKB1
KRAS
  • 1 views
  • 25 Jan, 2021
  • 16 locations
A Study of VLS-101 in Patients With Solid Tumors

This is a Phase 2 study evaluating the efficacy, safety, pharmacokinetics, immunogenicity, and pharmacodynamics of VLS-101 in patients with metastatic solid tumors. VLS-101 is an antibody- drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) on cancer cells.

  • 0 views
  • 11 Apr, 2021
  • 3 locations
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). …

breast cancer
systemic therapy
fulvestrant
metastatic cervical cancer
endocrine therapy
  • 0 views
  • 06 Jun, 2021
  • 15 locations
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

This prospective, unicentric, open-labe phase I study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of IIIB/IIIC/IV non-small cell lung cancer.

lung carcinoma
alopecia
carboplatin/paclitaxel
pd-1 inhibitor
paclitaxel
  • 3 views
  • 24 Jan, 2021
  • 1 location